You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
智利签署康希诺新冠疫苗采购协议 料第二季运抵
阿思达克 03-31 12:01
《新华社》报道,智利总统皮涅拉周二(30日)宣布,智利已签署中国康希诺(06185.HK)新冠疫苗采购协议。皮涅拉指,智利公共卫生研究院有望在短时间内批准康希诺新冠疫苗的紧急使用许可,预期康希诺新冠疫苗将在今年第二季运抵智利,助智利迅速普及新冠疫苗接种。

康希诺新冠疫苗是中国军事科学院军事医学研究院和康希诺公司联合研发的腺病毒载体疫苗,目前正在智利等国进行三期临床试验。该疫苗已在中国、墨西哥、巴基斯坦和匈牙利等国获得紧急使用许可。

智利於2月3日启动全国新冠疫苗大规模接种。截至3月30日,智利全国已有658万人接种了至少一剂疫苗。智利计划今年上半年完成1,500万人接种,约占人口总数的80%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account